Patents by Inventor Matthew J. Scanlan

Matthew J. Scanlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SSX family proteins
    Patent number: 6339140
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: January 15, 2002
    Assignees: Ludwig Institute for Cancer Research, Cornell Medical Research Foundation, Memorial Sloan Kettering Cancer Center
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules encoding SSX family members and thereof
    Patent number: 6291658
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: September 18, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
    Patent number: 6043084
    Abstract: Various molecules associated with disorders such as colon cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: March 28, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Yao-Tseng Chen, Elisabeth Stockert, Lloyd J. Old
  • Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
    Patent number: 5587299
    Abstract: The invention describes the identification and isolation of nucleic acid molecules which code for fibroblast activation protein alpha, or "FAP.alpha.". Various applications of the isolated molecules are also described.
    Type: Grant
    Filed: April 20, 1994
    Date of Patent: December 24, 1996
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Wolfgang J. Rettig, Matthew J. Scanlan, Pilar Garin-Chesa, Lloyd J. Old